News – Page 893 – Endpoints News

FDA requests additional time for Flexion's sNDA; Genentech releases data for PhIII study of Rituxan

6 years ago

BridgeBio drops bid to reclaim Eidos after directors spurn 3 offers

6 years ago

HR violation pushes Revance co-founder out, vaulting former Zeltiq chief to the helm

6 years ago

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

6 years ago

A predator's world? Top analyst sees the 'haves' and the 'haven'ts' diverge as biotech bubbles form — and collapse

6 years ago

Cell therapy startup raises $16 million to fund its quest for the Holy Grail in regenerative medicine

6 years ago

Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles

6 years ago

Pelosi drug pricing bill promises savings, but could gag R&D — CBO analysis

6 years ago

Pfizer takes aim at a flagship franchise at Sanofi and Regeneron — and scores a few direct hits

6 years ago

First place finish: Eli Lilly just moved to franchise leader with their second migraine drug OK in 1 year

6 years ago

ARCH, SoftBank-backed Vir Biotechnology underwhelms with $143 million IPO

6 years ago

Court green-lights Clovis case after detailing evidence the board ‘ignored red flags’ on false safety and ...

6 years ago

Northwest Bio still hanging on; Five Prime's latest round of layoffs claims 70

6 years ago

Zosano Pharma CEO passes baton down to successor; James Sapirstein takes the helm at AzurRx

6 years ago

Microcap Aridis recruits Takeda vet Paul Mendelman to steer late-stage antibody programs in infectious diseases

6 years ago

Long term data echo safety profile of Gilead, Galapagos' potential blockbuster JAK inhibitor

6 years ago

Researchers find 15% of trials could be replicated using real world data

6 years ago

Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor

6 years ago

Roche vice-chair: Let's repair the damage that short-term profit drive has done to the planet

6 years ago

In reversal, NICE backs Rubraca after Clovis agrees to a price cut

6 years ago

J&J hands off non-opioid painkiller to an upstart in the race for next-gen analgesics

6 years ago

Zantac pulled off shelves due to cancer scare; The end of the road for Motif Bio

6 years ago

Flow of US biotech VC dollars on track to match record 2018 levels — China? Not so much

6 years ago

AbbVie uncoupling costs Reata $330M in cold, hard cash

6 years ago

First page Previous page 890 891 892893894 895 896 Next page Last page